This has been shown by the results of previous studies of neoadjuvant therapy with aromatase inhibitors in postmenopausal breast cancer patients.4, 7 In the present study, switching nonresponders from exemestane monotherapy to exemestane‐based chemotherapy did not increase the rate of conversion from mastectomy to BCS. Here, CYP19A1 is linked to breast carcinoma.